Wednesday 29 January 2020 ,
Wednesday 29 January 2020 ,
Latest News
  • China confirms 5,974 virus cases as death toll rises to 132
  • Candidates out to woo voters as electioneering ends today
  • Citizens miffed by loudspeaker use
  • 3 killed in Dinajpur road crash
  • DNCC to procure 42,450 streetlights
5 August, 2019 00:00 00 AM

FDA approves Accrufer (ferric maltol) for the treatment of Iron deficiency in adults

drugs.com
FDA approves Accrufer (ferric maltol) for the treatment of Iron deficiency in adults

Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Accrufer® (Feraccru® in the European Union and Switzerland) for the treatment of iron deficiency in adults.

With this broad label approval Accrufer (as the product will be marketed in the USA) has taken a big step towards exploiting the very large commercial opportunity in the USA, the world’s largest and most attractively reimbursed pharmaceutical market.

Market research suggests that the prescription market for iron replacement therapy in the USA is worth over $1.0bn annually. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and management estimate potentially two to three times this number require treatment for iron deficiency.

Accrufer’s confirmed efficacy, together with its good tolerability and mode of absorption - by which the body absorbs only as much iron from Accrufer as it needs - means that the product could be the ideal choice for iron deficient patients who cannot tolerate salt-based oral iron alternatives.

These features, combined with the noninferiority results from the AEGIS-H2H study announced in March 2019, mean that treatment with Accrufer might remove the need for patients to progress to intravenous iron therapy, leading to a change in the current paradigm for the treatment of iron deficiency anaemia.

Together with its advisors, Shield is in discussions with a number of potential commercial partners for the US opportunity for Accrufer and looks forward to providing updates on these discussions in due course.

Feraccru is already approved in both the European Union and Switzerland for the treatment of iron deficiency in adults and commercialisation activities in these territories are progressing well via Shield’s licensing partners.

Carl Sterritt, CEO of Shield Therapeutics: “We are delighted that the FDA has approved the new drug application for our lead asset. This is a further major milestone for the Company which we have worked tirelessly to achieve, and I am very proud to lead the team within Shield that has made this happen.

With this broad approval and IP protection out to 2035, Feraccru®/ Accrufer® has a real and very attractive long-term market opportunity to exploit in the USA.

We have been pleased with the levels of interest and engagement shown by 3rd parties in commercialising Accrufer® in the USA and we look forward to finalising these discussions and appointing a commercial partner In the world’s most attractive pharmaceutical market,so that more patients with iron deficiency can benefit from treatment with Accrufer® at the earliest opportunity.”

Jackie Mitchell, VP Regulatory Affairs of Shield Therapeutics: “The broad label that the FDA has granted provides a very strong signal as to the tolerability and efficacy profile of Feraccru®/ Accrufer® and provides a novel and convenient treatment alternative to the millions of US patients who routinely suffer with iron deficiency.

We believe that this broad approval, together with the recent clinical trial data on Feraccru® that showed it to be non-inferior in treatment effect to Ferinject®/ Injectafer®, the leading IV iron therapy, can lead to a change in the current paradigm for the treatment iron deficiency anaemia.”

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Leprosy or Hensen’s Disease is an infectious, chronic granulomatus disease caused by an acid and alcohol fast bacillus called Micobacterium Leprae.…
Q&A on Leprosy

Q&A on Leprosy

What is leprosy? Leprosy is a chronic, progressive bacterial infection caused by the bacterium Mycobacterium leprae. It primarily affects the nerves of…
Leprosy elimination

Leprosy elimination

Leprosy is a chronic infectious disease caused by Mycobacterium leprae, an acid-fast, rod-shaped bacillus. The disease mainly affects the skin, the peripheral…
Global Leprosy Strategy 2016-2020

Global Leprosy Strategy 2016-2020

The past three decades have witnessed some impressive advances in leprosy control. Elimination as a public health problem (i.e. registered prevalence…
Sepsis: Everything you need to know

Sepsis: Everything you need to know

Sepsis is a life-threatening illness caused by body's response to an infection. This infection injures its own tissues and organs, potentially leading…
Mystery virus in Wuhan identified as novel coronavirus

Mystery virus in Wuhan identified as novel coronavirus

Chinese authorities have been commended for the speed at which they have identified the genetic make up of a novel coronavirus, 2019-nCoV as the cause…
Belly fat linked with repeat heart attacks

Belly fat linked with repeat heart attacks

Heart attack survivors who carry excess fat around their waist are at increased risk of another heart attack, according to research published today in…
5 Things to do after your child is diagnosed with autism

5 Things to do after your child is diagnosed with autism

KACIE After my daughter was diagnosed with autism, I learned five important lessons I want to pass on to other families. There is a lot more to this list…
BAUS Conf 2020

BAUS Conf 2020

14th  BAUS Conference 2020 of Bangladesh Association of Bangladesh Association of Urological Surgeons was held at Intercontinental Hotel, Dhaka on…
'Alarming' one in five deaths due to sepsis

'Alarming' one in five deaths due to sepsis

JAMES GALLAGHER   One in five deaths around the world is caused by sepsis, also known as blood poisoning, shows the most comprehensive analysis of…
FDA warns of surgical gowns that may not be sterile

FDA warns of surgical gowns that may not be sterile

Certain surgical gowns and surgical packs made by Cardinal Health may not be sterile and should not be used, the U.S. Food and Drug Administration said…
FDA approves Ozempic (semaglutide) for cardiovascular risk reduction in adults with Type 2 Diabetes and known heart disease

FDA approves Ozempic (semaglutide) for cardiovascular risk reduction in adults with Type 2 Diabetes and known heart disease

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic (semaglutide) injection 0.5 mg…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting